BCI Predictive
BCI Predictive (sometimes called H over I, written as H/I) provides a likelihood of benefit from extended (>5 year) anti-estrogen therapy in women who are recurrence-free after an initial 5 years of anti-estrogen therapy. This is reported as HIGH Likelihood or LOW Likelihood. As many such tests, there is retrospective validation but no prospective studies to support it use, meaning that utilizing this test to select therapy has not been shown to be beneficial andit is not recommended by any guidelines.
Dennis C. Sgroi, Judy-Anne W. Chapman, T. Badovinac-Crnjevic, Elizabeth Zarella, Shemeica Binns, Yi Zhang, Catherine A. Schnabel, Mark G. Erlander, Kathleen I. Pritchard, Lei Han, Lois E. Shepherd, Paul E. Goss, Michael Pollak, Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA… Breast Cancer Research January 2016